Tags

Type your tag names separated by a space and hit enter

Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery.
J Clin Anesth. 2009 Jun; 21(4):249-52.JC

Abstract

STUDY OBJECTIVE

To determine the efficacy of transdermal scopolamine in addition to ondansetron in decreasing the incidence of postoperative nausea and vomiting (PONV).

DESIGN

Randomized controlled trial.

SETTING

Academic hospital.

PATIENTS

126 ASA physical status I and II patients undergoing outpatient plastic surgery with three or more risk factors for PONV.

INTERVENTIONS

Patients were randomly assigned to one of two groups to receive (Group 1) a transdermal scopolamine (TDS) patch or (Group 2), a placebo patch two hours before surgery.

MEASUREMENTS

Occurrence of vomiting, severity of nausea using a visual analog scale (VAS), rescue medication, pain intensity and pain medications, and side effects were recorded every hour until discharge from hospital, then every 4 hours thereafter for a total of 24 hours.

MAIN RESULTS

A statistically significant reduction in postoperative nausea between 8 and 24 hours in patients receiving TDS was noted.

CONCLUSIONS

Transdermal scopolamine in addition to ondansetron benefits patients at high risk for PONV undergoing outpatient plastic surgery for up to 20 hours after surgery.

Authors+Show Affiliations

Department of Anesthesiology, Magee Womens Hospital and the University of Pittsburgh, Pittsburgh, PA 15213, USA. sahxnb@anes.upmc.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

19502023

Citation

Sah, Neera, et al. "Transdermal Scopolamine Patch in Addition to Ondansetron for Postoperative Nausea and Vomiting Prophylaxis in Patients Undergoing Ambulatory Cosmetic Surgery." Journal of Clinical Anesthesia, vol. 21, no. 4, 2009, pp. 249-52.
Sah N, Ramesh V, Kaul B, et al. Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery. J Clin Anesth. 2009;21(4):249-52.
Sah, N., Ramesh, V., Kaul, B., Dalby, P., Shestak, K., & Vallejo, M. C. (2009). Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery. Journal of Clinical Anesthesia, 21(4), 249-52. https://doi.org/10.1016/j.jclinane.2008.08.017
Sah N, et al. Transdermal Scopolamine Patch in Addition to Ondansetron for Postoperative Nausea and Vomiting Prophylaxis in Patients Undergoing Ambulatory Cosmetic Surgery. J Clin Anesth. 2009;21(4):249-52. PubMed PMID: 19502023.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery. AU - Sah,Neera, AU - Ramesh,Vimala, AU - Kaul,Bupesh, AU - Dalby,Patricia, AU - Shestak,Kenneth, AU - Vallejo,Manuel C, Y1 - 2009/06/06/ PY - 2007/05/07/received PY - 2008/07/14/revised PY - 2008/08/02/accepted PY - 2009/6/9/entrez PY - 2009/6/9/pubmed PY - 2009/9/3/medline SP - 249 EP - 52 JF - Journal of clinical anesthesia JO - J Clin Anesth VL - 21 IS - 4 N2 - STUDY OBJECTIVE: To determine the efficacy of transdermal scopolamine in addition to ondansetron in decreasing the incidence of postoperative nausea and vomiting (PONV). DESIGN: Randomized controlled trial. SETTING: Academic hospital. PATIENTS: 126 ASA physical status I and II patients undergoing outpatient plastic surgery with three or more risk factors for PONV. INTERVENTIONS: Patients were randomly assigned to one of two groups to receive (Group 1) a transdermal scopolamine (TDS) patch or (Group 2), a placebo patch two hours before surgery. MEASUREMENTS: Occurrence of vomiting, severity of nausea using a visual analog scale (VAS), rescue medication, pain intensity and pain medications, and side effects were recorded every hour until discharge from hospital, then every 4 hours thereafter for a total of 24 hours. MAIN RESULTS: A statistically significant reduction in postoperative nausea between 8 and 24 hours in patients receiving TDS was noted. CONCLUSIONS: Transdermal scopolamine in addition to ondansetron benefits patients at high risk for PONV undergoing outpatient plastic surgery for up to 20 hours after surgery. SN - 1873-4529 UR - https://www.unboundmedicine.com/medline/citation/19502023/Transdermal_scopolamine_patch_in_addition_to_ondansetron_for_postoperative_nausea_and_vomiting_prophylaxis_in_patients_undergoing_ambulatory_cosmetic_surgery_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0952-8180(09)00087-7 DB - PRIME DP - Unbound Medicine ER -